An NCI-designated Comprehensive Cancer Center
Horne-David

David Horne, Ph.D.

Vice Provost and Associate Director, Beckman Research Institute of City of Hope; Acting Dean, Irell & Manella Graduate School of Biological Sciences; Dr. & Mrs. Allen Y. Chao Chair in Developmental Cancer Therapeutics; Professor, Department of Molecular Medicine; Dean of Faculty Affairs; Interim Chair, Department of Information Sciences; Director, Synthetic and Biopolymer Chemistry Core; Co-director, Drug Discovery and Structural Biology; Co-leader for Developmental Cancer Therapeutics
Research Focus
  • Driving Drug Discovery through Natural Products, Individualized Medicine, and Creation of New Platform Technologies
  • COH29: A Novel Small Molecule Inhibitor of Ribonucleotide Reductase and DNA Repair
  • LEO-12-1406: A Novel Small Molecule Inhibitor of Histone Methyltransferase SUV39H1
  • Indirubins and Stat3: An active anti-cancer component of the Traditional Chinese Medicine Dang Gui Long Hui Wan
Contact
Email: [email protected]

David Horne, Ph.D., is vice provost and associate director of Beckman Research Institute of City of Hope and dean of faculty affairs. In this role, he oversees the Irell & Manella Graduate School of Biological Sciences, the Postdoctoral Training Office, International Research Programs and the Office of Faculty Affairs. Dr. Horne and Steven T. Rosen, M.D., provost and chief scientific officer, are institutional leaders in all aspects of academic scientific and medical education, shaping the scientific and educational vision for City of Hope. As associate director, Dr. Horne assists Dr. Rosen in his responsibilities as director of Beckman Research Institute of City of Hope.

Dr. Horne is well-known for his scientific and research expertise, as well as his ability to build strong relationships with faculty and leaders across our organization and at partnering institutions. He has held numerous leadership positions since first joining Beckman Research Institute of City of Hope in 2006, including his most recent role as interim director. Dr. Horne’s professional experience is complemented by impressive academic achievements in the area of medicinal chemistry and drug development. Dr. Horne holds a Ph.D. in chemistry from the Massachusetts Institute of Technology and B.S. in chemistry from UCLA. He was a National Institutes of Health postdoctoral fellow at the California Institute of Technology, as well as a Beckman Young Investigator and National Science Young Investigator Awardee.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Yadav S, Kowolik C, Lin M, Zuro D, Hui S, Riggs A, Horne D. SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties. Molecular Carcinogenesis 2019 58(1): 113-125.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovsa T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Xu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST. 8-Chloro-Adenosine Activity in FLT3-ITD Acute Myeloid Leukemia.” Journal of Cellular Physiology 2019, DOI: 10.1002/jsp.28294. [Epub ahead of print]

Baumann M, Dieskau AP, Loertscher BM, Walton MC, Nam S, Xie J, Horne D, Overman LE. Tricyclic analogues of epidithiodioxopiperazine alkaloids with promising in vitro and in vivo antitumor activity. Chem. Sci. 2015, 6, 4451-4457.

Singhal SS, Singhal J, Figarola JL, Riggs A Horne D, Awasthi S. 2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention. Biochem. Pharmacol. 2015 (pages ahead of print).

Singhal SS, Singhal J, Figarola J, Horne D, Awasthi S. LIP76 Targeted Therapy for Kidney Cancer. Pharmaceut. Res. 2015, (pages ahead of print)

Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh M-Y, Horne D, Dellinger TH, Han ES, Jove R, Yim, JH. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer, 2015, 14, 1-21.

Korch KM, Eidamshaus C, Behenna DC, Nam S, Horne D, Stoltz BM. Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angew. Chem. Int. Ed. 2015, 54, 179-183.

Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh M-Y, Hong H, Brown CE, Forman SJ, Horne D, Morgan R, Wakabayashi M, Dellinger TH, Han ES, Yim JH, Jove R. Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer. Mol. Cancer Ther. 2014, 13(12), 3037-3048.

Wang Y, Han E, Xing Q, Yan J, Arrington A, Wang C, Tully D, Kowolik CM, Lu DM, Frankel PH, Zhai J, Wen W, Horne D, Yip MLR, Yim JH. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Lett. 2015, 358, 170-179.

Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, Conti PS, Li Z, Kandeel F, Shively JE. Facile preparation of a thiol-reactive 18F-labeling agent and synthesis of 18F-DEG-VS-NT for PET imaging of a neurotensin receptor-positive tumor. J. Nucl. Med. 2014, 55, 1178-1184.

Fan Y, Nam S, Zhao R, Ma Y, Xie J Horne DA, Brown CE, Starr R, Malkas LH, Jove R, Hickey R. J. A Novel Berbamine Derivative Inhibits Cell Viability and Induces Apoptosis in Cancer Stem-Like Cells of Human Glioblastoma, via Up-Regulation of miRNA-4284 and JNK/AP-1 Signaling. PLoS One 2014, 9, e100708.

Shubbir A, Xie J, Horne D, Williams JC. Photocleavable Dimerizer for the Rapid Reversal of Molecular Trap Antagonists. J. Biol. Chem. 2014, 289, 4546-52.

Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC. Identification and Grafting of a Unique Peptide-Binding Site in the Fab Framework of Monoclonal Antibodies. Proc. Natl. Acad. Sci. 2013, 110, 17456-61.

DeLorbe JE, Horne D, Jove R, Mennen SM, Nam S, Zhang F-L, Overman LE. General Approach for Preparing Epidithiodioxopiperazines from Trioxopiperazine Precursors: Enantioselective Total Syntheses of (+)- and (-)-Gliocladine C, (+)-Leptosin D, (+)-T988C, (+)-Bionectin A, and (+)-Gliocladin A. J. Am. Chem. Soc. 2013, 135, 4117-4128.

Zhou B, Su L, Hu S, Hu W, Yip MLR, Wu J, Gaur S, Smith DL, Yuan Y-C, Synold TW, Horne D, Yen Y. A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance. Cancer Res 2013, 73, 6484-6493.

Lu L, Zhang W, Nam S, Horne DA, Jove R, Carter RG. Amphidinolide B: Total Synthesis, Structural Investigation, and Biological Evaluation. J. Org. Chem. 2013, 78, 2213-2247.

 

In The News
An Expert's Voice
breakthroughs - arthur riggs

Reeling in the Past: Research Gives New Life to Old Model of DNA Looping

Zeng-Defu

Novel Treatment May Stop Graft-Versus-Host Disease

Peter Lee

Peter P. Lee, M.D.: Chasing Cancer from All Angles